A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109
Completed
- Conditions
- abdominal pain and heartburn10017943
- Registration Number
- NL-OMON30044
- Lead Sponsor
- Janssen-Cilag
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 82
Inclusion Criteria
Healthy males without evidence of gastro-intestinal disorders
Exclusion Criteria
Subjects with evidence of clinically significant reproductive, gastrointestinal, renal, hematologic, pulmonary, neurologic, respiratory, endocrine/metabolic, or cardiovascular system abnormalities, psychiatric disorders, oncologic conditions or acute or chronic infection.
Subjects with a history of any hepatic disorder or history of hepatitis.
Subjects with known elevations of LFTs, alkaline phosphatase, gamma-GT, or bilirubin in the past.
Negative Helicobacter pylori serum IgG antibody
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method